Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02611661 · ClinicalTrials.gov registry record · Phase 1

Local Ablative Strategies After Endovascular Radioembolization

A Phase 1 study, sponsored by Washington University School of Medicine.

Terminated
Registry status
Phase 1
Development phase
9
Enrollment target

NCT02611661 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 9 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02611661, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.

TERMINATED
Registry status
Phase 1
Development phase
9 participants
Enrollment target

Study Summary

The rationale for this design is initial utilization of a standard-of-care therapy for mCRC (radioembolization) with a dose-calculation algorithm that has been verified as predictive for treatment response. Prediction of treatment failure will enable the proposed subsequent locoregional therapies which were selected based on safety profiles and feasibility. While the goal of this study is assessing feasibility and safety of this approach, the end goal of improving overall patient outcomes by improved hepatic tumor control.

Interventions

  • DEVICE PET/MRI
  • RADIATION Stereotactic body radiotherapy
  • RADIATION Percutaneous ablation

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2016-01-19
Est. Completion 2018-02-13
Phase Phase 1

What the Registry Record Tells You About NCT02611661

The ClinicalTrials.gov registry entry for NCT02611661 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which PET/MRI is the first listed.

NCT02611661 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02611661 about?

NCT02611661 is a clinical study titled "Local Ablative Strategies After Endovascular Radioembolization". The rationale for this design is initial utilization of a standard-of-care therapy for mCRC (radioembolization) with a dose-calculation algorithm that has been verified as predictive for treatment response. Prediction of treatment failure will enable the proposed subsequent locoregional therapies wh...

What is the current status of trial NCT02611661?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-01-19. Estimated completion is 2018-02-13.

What interventions are being tested in trial NCT02611661?

The interventions under investigation include: PET/MRI (DEVICE), Stereotactic body radiotherapy (RADIATION), Percutaneous ablation (RADIATION).

Who is sponsoring clinical trial NCT02611661?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.